EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-15

Study Completion Date

2027-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population (Pinal-Fernandez et al. 20145; JInnin M 20186) do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis

NCT06231498

Eosinophilic Granulomatosis With Polyangiitis

NOT_YET_RECRUITING

Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis

NCT00441961

Fasciitis

COMPLETED NA

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

NCT00001541

Inflammation Vasculitis Wegener's Granulomatosis

COMPLETED

Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis

NCT06004817

Dermatomyositis

RECRUITING

Natural History of Hypereosinophilia and Hypereosinophilic Syndromes

NCT04018118

Eosinophilia Hypereosinophilic Syndrome

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eosinophilic Fasciitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Juvenile eosinophilic fasciitis

Age \< 18 years at diagnosis

\- The study will include two different populations:

1. Patients who have received a diagnosis of JEF based on deep fascial biopsy characteristics.
2. Patients who have received a diagnosis of JEF based on typical MRI findings, but without performing a deep fascial biopsy.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients diagnosed from 2000 to 31/12/2026

* minimum follow-up 6 months
* Age \<18 years at diagnosis;
* All patients whose informed consent is collected in accordance with current local legislation will also be considered enrollable.